2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH DENA BATTLE
Patient Perspectives on Cytoreductive Nephrectomy after the CARMENA Trial

VIEW ALL ASCO GU 2019 VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH OLIVER SARTOR
Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer

VIEW ALL PCF VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH KARIM FIZAZI
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC

VIEW ALL ASCO GU 2019 VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH JAMES GULLEY
Immunotherapy Across Genitourinary Malignancies

VIEW ALL ASCO GU 2019 VIDEOS

Featured Videos

#AUA14 - Efficacy and long-term safety analysis of study COU-AA-302: Abiraterone acetate plus prednisone in chemotherapy-naïve metastatic castration-resistant prostate cancer - Session Highlights

ORLANDO, FL USA (UroToday.com) - Dr. Neal Shore presented an abstract on a multi-institutional study evaluating the safety and tolerability of long-term treatment (≥ 24 months) and also reported on the efficacy at 56% overall survival (OS) events of study COU-AA-302. In study COU-AA-302, 1 088 patients were randomized 1:1 to abiraterone (AA) 1000 mg + prednisone (P) 5 mg po BID vs placebo + P. “Co-primary” end points were radiographic progression-free survival (rPFS) and OS. Kaplan-Meier was used to estimate the 95% confidence interval (CI) of the end points and median times. Moreover, efficacy analysis and post hoc analysis of adverse events (AEs) was performed at the pre-specified third interim analysis (IA3).

auaAt IA3, the median follow-up was 27.1 months. rPFS, (HR=0.53 [95% CI], (0.45-0.62), p < 0.0001), and OS (HR=0.79 [95%CI], (0.66-0.96), p = 0.0151), were improved over P; the latter did not reach the pre-specified efficacy boundary (p = 0.0035). All reported secondary end points favored the AA arm of the study. In regards to adverse effects, grade 3/4 AEs (AA + P vs P) were reported as: hypokalemia (3% vs 2%); hypertension (4% vs 3%); increase in alanine aminotransferase (6% vs 1%); and also increase in aspartate aminotransferase (3% vs 1%). Dr. Shore showed the date illustrating that prolonged exposure to AA + P was safe and well tolerated vs P alone among most men. Moreover AA + P did not clinically show any relevant increase in the incidence rate of grade 3/4 AEs with ≥ 24 months drug exposure. The percentage of patients who came off the study due to an AE was reported as 8% (AA) vs 6% (P).

Abiraterone acetate is a selective androgen biosynthesis inhibitor that prolongs OS in patients with mCRPC and is approved for use in this population. This study shows that the updated IA3 of COU-AA-302 causes delay in progression and prolongation of life with a favorable safety profile, including patients who were treated for more than 24 months with AA + P or P.

Presented by Neal D. Shore, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Myrtle Beach, SC USA

Written by Reza Mehrazin, MD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 3 Issue 4

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe